Introduction
Major histocompatibility complex (MHC) class I molecules consist of a highly polymorphic MHC-encoded heavy chain (HC; M r ' 32 000) that is noncovalently associated with an invariant protein [ 2 -microglobulin ( 2 m), M r ' 12 000]. The HC forms a groove that is able to bind peptides, usually with a length of 8-13 amino acids, in an allele-dependent fashion (Madden, 1995) . These peptides are typically derived from fragmented intracellular proteins that may also include viral antigens in the case of a virus-infected cell. The involvement of the MHC in disorders that are characterized by cellular or antibody responses against self-antigens (autoimmune diseases) is insufficiently understood. This is exemplified by the human MHC class I allele HLA-B27 and ankylosing spondylitis (AS; Brewerton et al., 1973; Schlosstein et al., 1973) , which exhibits the strongest known association of a disease with an HLA class I allele (Horton et al., 2004) . Recently, HLA-B*1403, an allele present only in African populations of Cameroon and Togo, was reported to be associated with AS in the Togolese population (Ló pez-Larrea et al., 2002) , where both this disease and HLA-B27 are rare. The closely related allele HLA-B*1402 has a widespread distribution that also includes Caucasians, but has never been found to be associated with AS. The products of these subtypes differ only at residue 156 (Leu in HLA-B*1402, Arg in HLA-B*1403). HLA-B*2705 differs from the two HLA-B14 HCs at 18 amino-acid positions located within the first two domains (1 and 2) of the extracellular region of the molecules.
A considerable research effort has been devoted towards unravelling the molecular basis of this disease association, but no indepth understanding of AS pathogenesis has yet been obtained (Khan & Ball, 2002; Ló pez de Castro, 2007) . As there are suggestions that the recognition of HLA class I complexes by cytotoxic T lymphocytes (CTL) or natural killer cells might play a role in the pathogenesis (Benjamin & Parham, 1990; Ló pez de Castro, 2007) , peptide presentation by these molecules has provided a research focus in the last decade. AS patients with the HLA-B*2705 subtype have been found to possess elevated levels of CTL directed against the self-peptide pVIPR (RRKWRRWHL, derived from vasoactive intestinal peptide type 1 receptor, residues 400-408), about one sixth of which cross-react with HLA-B*2705-positive cells presenting the viral pLMP2 peptide (RRRWRRLTV, derived from latent membrane protein 2 of Epstein-Barr virus, residues 236-244) (Fiorillo et al., 2000 (Fiorillo et al., , 2005 . Individuals with another subtype, HLA-B*2709, the product of which differs from that of HLA-B*2705 at only one position (Asp116 in HLA-B*2705, His116 in HLA-B*2709), do not possess CTL that cross-react with the self-peptide pVIPR (Fiorillo et al., 2000) , suggesting the existence of an HLA-B27 subtypedependent correlation with AS pathogenesis.
A major feature of HLA-B27 ligands is the presence of arginine at position 2 (pArg2; Jardetzky et al., 1991; Madden et al., 1992; Urban et al., 1994; Ló pez de Castro et al., 2004) , which binds tightly into the socalled B pocket of the molecule's peptide-binding groove. Since this pocket is made up of residues that are polymorphic among HLA class I molecules, few allotypes other than HLA-B27, such as HLA-B14, bind peptides with pArg2 (Merino et al., 2005) . Two peptides were found to be shared by HLA-B*1402, HLA-B*1403, HLA-B*2705 and HLA-B*2709 (Merino et al., 2005 and unpublished work) . One of these is a self-peptide (pCatA, IRAAPPPLF) derived from the signal sequence (residues 2-10) of cathepsin A.
In contrast to the high degree of overlap among the constitutive peptide repertoires of HLA-B27 subtypes , HLA-B*1402 and HLA-B*1403 differ considerably regarding the peptides that are bound within the binding groove of the molecules (Merino et al., 2005) . However, the HLA-B27-bound and HLA-B14-bound peptide repertoires show even less overlap (about 3-5%; Merino et al., 2005) , although both pairs of subtypes share some important peptide-binding properties, such as the preference for pArg2, with HLA-B27 exhibiting a much higher restriction for this motif. It may therefore be envisaged that a thorough structural study of the HLA-B14 antigens and their comparison with the extensive structural findings in the HLA-B*2705/HLA-B*2709 system (Hü lsmeyer et al., 2002 (Hü lsmeyer et al., , 2004 Hillig et al., 2004; Fiorillo et al., 2005; Rü ckert et al., 2006) would enhance our understanding of the differential AS association of these four HLA-B subtypes and would help to shed light on the generality of the arthritogenic peptide theory (Ló pez de Castro, 2007).
Materials and methods

Protein preparation
The nonapeptides pLMP2 (RRRWRRLTV) and pCatA (IRAA-PPPLF) were chemically synthesized and purified by reverse-phase HPLC (EZBiolab, Westfield, USA). The HLA-B*1402 HC (Merino et al., 2005) was cloned into the pHN vector. Both HC and 2 m were untagged. They were expressed separately and formed inclusion bodies in Escherichia coli that were solubilized with 50%(w/v) urea. The HLA-B14-peptide complexes were prepared by reconstituting the HC (12 mg), 2 m (10 mg) and the respective peptide (4 mg) according to a previously described procedure (Garboczi et al., 1992) . Briefly, the reconstitution mixture (400 ml, containing 400 mM arginine-HCl, 2 mM EDTA, 5 mM reduced glutathione, 0.5 mM oxidized glutathione and 100 mM Tris-HCl pH 7.5) was incubated at 277 K for 8-12 weeks, concentrated using Amicon Ultra-15 concentrators and purified by size-exclusion chromatography with Sephadex 75 (Phar-macia). Fractions containing the respective ternary complex were pooled and their composition (HC, 2 m) was surveyed by SDS-PAGE. The protein complexes were then concentrated to 15 mg ml À1 using Amicon Ultra-15 in a buffer system containing 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.01%(w/v) sodium azide and used for crystallization trials.
Crystallization and data collection
For the HLA-B*1402-pLMP2 complex, a high-throughput robotic crystallization station (Protein Structure Factory, Berlin, Germany; Heinemann et al., 2000) was used to screen several standard crystallization screen kits from Hampton Research (Aliso Viejo, USA). Sitting-drop vapour-diffusion crystallization trays with 100 ml reservoir solution and 500 nl drops consisting of equal volumes of reservoir and protein solutions were set up and the trays were kept at 291 K for crystal formation. Crystals of HLA-B*1402-pLMP2 that diffracted to 2.74 Å resolution grew in 3 d over a well containing 20%(w/v) polyethylene glycol (PEG) 10 000 and 0.1 M HEPES buffer pH 7.5. Crystallization trials for the HLA-B*1402-pCatA complex were performed in a hanging-drop vapour-diffusion setup at 291 K (1 ml reservoir solution, 2 ml drops consisting of equal volumes of reservoir and protein solutions), but otherwise under conditions identical to those used for crystallizing HLA-B*1402-pLMP2. Crystals diffracting to 2.35 Å were obtained in 5 d in a well containing 24%(w/v) PEG 10 000, 0.1 M HEPES buffer pH 7.5.
Since the initially grown crystals were too small for X-ray analysis, the crystallization conditions for HLA-B*1402-pLMP2 and HLA-B*1402-pCatA were optimized by varying the molecular weight of the PEG and the concentrations of the various constituents in the hanging-drop trays. Drops were streak-seeded with crushed crystals of the same complex from previous experiments using cat whiskers. Thin plate-like hexagonal crystals of HLA-B*1402-pLMP2 with maximum dimensions of about 150 Â 100 Â 5 mm grew in 20-22%(w/v) PEG 20 000, 0.1 M HEPES buffer pH 7.5 and 24%(w/v) PEG 8000, 0.1 M HEPES buffer pH 7.5, while needle-shaped crystals of HLA-B*1402-pCatA with maximum dimensions of about 300 Â 10 Â 5 mm grew under similar conditions in 24-27%(w/v) PEG 20 000 with 0.1 M HEPES pH 7.5. Crystals of both complexes were finally transferred to cryoprotectant solution containing the respective reservoir solution and glycerol. The optimum concentrations of glycerol were found to be 20%(w/v) for HLA-B*1402-pLMP2 crystals and 15%(w/v) for HLA-B*1402-pCatA crystals.
X-ray diffraction data sets were collected for both complexes at 100 K on beamline 14.2 at the BESSY II synchrotron facility in Berlin, Germany using a wavelength of 0.91841 Å . The beamline is equipped with a fast-scanning CCD detector from MAR Research (Norderstedt, Germany). The crystals were exposed for 6.75-10 s during data collection. The HLA-B*1402-pLMP2 crystal was flashannealed (Harp et al., 1998) by shielding the cryostream for about 5 s. The crystals of the HLA-B*1402-pLMP2 and HLA-B*1402-pCatA complexes belonged to space groups P2 1 and P2 1 2 1 2 1 and diffracted to 2.55 and 1.85 Å resolution, respectively. The collected data sets were integrated and scaled using the HKL-2000 suite (Otwinowski & Minor, 1997) . There are two complexes and one complex per crystal asymmetric unit in the HLA-B*1402-pLMP2 and HLA-B*1402-pCatA crystals, respectively. Their Matthews coefficients and solvent contents (Matthews, 1968 ) were calculated to be 2.5 Å 3 Da À1 and 50.2%, and 2.6 Å 3 Da À1 and 52.2%, respectively, based on an approximate M r of $45 000 for each of the complexes. Crystallographic data and X-ray data-collection statistics are summarized in Table 1 .
crystallization communications
The CCP4 suite (Collaborative Computational Project, Number 4, 1994) program Phaser (Storoni et al., 2004) Models of both HLA-B*1402 complexes pack sensibly in the unit cells and show no clashes. Examination of electron-density maps calculated from the initial phases permitted us to identify the presence of the respective nonapeptides as well as the HC residues unique to HLA-B*1402 in both structures. Modelling of the respective peptides in electron density and rigid-body refinement yielded models with R and R free of 0.262 and 0.342, respectively, and an F o À F c correlation coefficient of 0.882 for HLA-B*1402-pLMP2, and R and R free values of 0.256 and 0.285, respectively, and an F o À F c correlation coefficient of 0.901 for HLA-B*1402-pCatA.
Results and discussion
Highly pure HLA-B*1402-pLMP2 and HLA-B*1402-pCatA complexes (Fig. 1) were crystallized using PEG as precipitant. Crystal formation was optimized by varying the PEG molecular weight and concentration as well as by streak-seeding using crystals of the same complex from previous experiments, which resulted in well ordered crystals (Fig. 2 ). X-ray diffraction analysis (Fig. 3) revealed that the crystals of the two complexes were non-isomorphous and belonged to space groups P2 1 and P2 1 2 1 2 1 , respectively, which are also typical for Matthews (1968) . ‡ R sym = P h P i jI h;i À hIij= P h P i I h;i . § According to Weiss (2001) . HLA-B27-peptide complexes (see, for example, Hü lsmeyer et al. , 2002, 2004, 2005) . Previously described crystals of HLA-B27 subtypes with the pLMP2 peptide belong to either space group P2 1 (HLA-B*2705 and HLA-B*2709; Fiorillo et al., 2005) or P2 1 2 1 2 1 (HLA-B*2703, HLA-B*2704 and HLA-B*2706; Loll, Zawacka, Biesiadka, Petter et al., 2005; Zawacka et al., 2005) . However, two complexes per asymmetric unit as found for HLA-B*1402-pLMP2 have not been observed in any crystal of HLA-B27-pLMP2. Information with regard to the conformation of the bound peptide cannot be inferred from these similarities or differences, since crystals of HLA-B*2705-pLMP2 and HLA-B*2709-pLMP2, which are near-isomorphous and share the same space group (P2 1 ), nevertheless display the pLMP2 peptide in completely different binding modes (Fiorillo et al., 2005) . Modelling of solvent molecules in unassigned electron density is in progress for both structures and complete structural details will be reported separately.
The structure of the HLA-B*1402 complexes will permit comparison with other previously determined structures of HLA-B27 molecules in complex with these peptides, enabling a direct assessment of the binding mode of the same peptide (pLMP2) in complex with significantly distinct HLA class I molecules. A detailed structural study of peptide presentation by these complexes will improve our understanding of HLA-B subtype-dependent T-cell recognition and might also shed light on the causes underlying the association of certain HLA-B27 and HLA-B14 alleles with spondyloarthropathies.
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